肌层浸润性膀胱癌患者的新辅助化疗：哪些患者受益？
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
机构信息
Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany.
出版信息
Eur Urol. 2013 Sep;64(3):355-7. doi: 10.1016/j.eururo.2013.06.002. Epub 2013 Jun 12.
PMID:23773558
Abstract
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
摘要
一级证据支持新辅助化疗治疗晚期膀胱癌。为了获得最大益处，建议将新辅助化疗仅限于临床 T3 疾病和/或临床 N+疾病患者。
Zotero 插件